Macquarie Group LTD Syndax Pharmaceuticals Inc Transaction History

Macquarie Group LTD

$90.3 Billion
Q3 2024

A detailed history of Macquarie Group LTD transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Macquarie Group LTD holds 243,352 shares of SNDX stock, worth $3.18 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

243,352

Previous 242,919 0.18%

Holding current value

$3.18 Million

Previous $4.99 Million 6.08%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$17.93 - $24.81 $7,763 - $10,742	433 Added 0.18%	243,352 $4.68 Million
Q2 2024 Aug 09, 2024	SELL	$18.82 - $23.79 $1,373 - $1,736	-73 Reduced 0.03%	242,919 $4.99 Million
Q1 2024 May 14, 2024	SELL	$19.71 - $24.57 $21,641 - $26,977	-1,098 Reduced 0.45%	242,992 $5.78 Million
Q4 2023 Feb 14, 2024	BUY	$11.39 - $21.67 $132,397 - $251,892	11,624 Added 5.0%	244,090 $5.27 Million
Q3 2023 Nov 14, 2023	BUY	$14.52 - $21.77 $14,853 - $22,270	1,023 Added 0.44%	232,466 $3.38 Million
Q2 2023 Aug 14, 2023	BUY	$19.35 - $22.31 $995,422 - $1.15 Million	51,443 Added 28.58%	231,443 $4.84 Million
Q3 2022 Nov 14, 2022	SELL	$18.51 - $24.79 $18,343 - $24,566	-991 Reduced 0.55%	180,000 $4.35 Million
Q1 2021 May 14, 2021	BUY	$19.28 - $24.59 $19,106 - $24,368	991 Added 0.55%	180,991 $4.05 Million
Q2 2018 Aug 14, 2018	BUY	$6.93 - $14.63 $1.25 Million - $2.63 Million	180,000 New	180,000 $1.26 Million
Q1 2018 May 11, 2018	SELL	$8.71 - $14.82 $10,452 - $17,784	-1,200 Closed	0 $0
Q4 2017 Feb 15, 2018	BUY	$7.8 - $12.94 $9,360 - $15,528	1,200	1,200 $11,000

Others Institutions Holding SNDX

# of Institutions

228

Shares Held

88.4M

Call Options Held

1.01M

Put Options Held

692K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $740M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Account

Macquarie Group LTD Syndax Pharmaceuticals Inc Transaction History